Krystal Biotech, Inc. (KRYS)

NASDAQ: KRYS · IEX Real-Time Price · USD
177.93
+0.73 (0.41%)
At close: Mar 28, 2024, 4:00 PM
182.15
+4.22 (2.37%)
After-hours: Mar 28, 2024, 7:15 PM EDT

Company Description

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.

It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech, Inc.
Krystal Biotech logo
Country United States
Founded 2015
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 229
CEO Krish S. Krishnan M.B.A., M.S.

Contact Details

Address:
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
United States
Phone (412) 586-5830
Website krystalbio.com

Stock Details

Ticker Symbol KRYS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001711279
CUSIP Number 501147102
ISIN Number US5011471027
Employer ID 82-1080209
SIC Code 2836

Key Executives

Name Position
Krish S. Krishnan M.B.A., M.S. Founder, Chairman, President and Chief Executive Officer
Suma M. Krishnan Founder, Chief Operating Officer, President of Research & Development and Director
Kathryn A. Romano Executive Vice President and Chief Accounting Officer
John Thomas General Counsel and Corporate Secretary
John Karakkal Vice President of North American Sales and Marketing
Christine Wilson Head of U.S. Sales and Marketing
Josh Suskin Director of Human Resources and Operations
Dr. Hubert C. Chen M.D. Senior Vice President of Clinical Development
Laurent Goux Senior Vice President and GM of Europe
Ram Kamineni Senior Vice President of CMC and Technical Operations

Latest SEC Filings

Date Type Title
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 26, 2024 144 Filing
Feb 26, 2024 8-K Current Report
Feb 26, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 26, 2024 10-K Annual Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals